Janux Therapeutics, Inc. (JANX)

Janux Therapeutics' stock price has been impacted by several events in the past six months. In December 2025, the stock declined significantly after updated clinical data for JANX007 showed a decrease in objective response rate. In February 2026, the company reported better-than-expected fourth-quarter earnings per share. In April 2026, Janux Therapeutics received a $35 million milestone payment from Bristol Myers Squibb.

As a clinical-stage biopharmaceutical company, Janux Therapeutics does not have commercialized products generating direct sales revenue. Its revenue is primarily derived from collaborations, licensing agreements, and milestone payments from partnerships. Therefore, traditional product demand seasonality does not apply to Janux Therapeutics' current business model.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and autoimmune diseases. Founded in 2017 and based in San Diego, California, it operates in the Biotechnology industry. Janux utilizes its proprietary technology platforms to create novel drug candidates that generate immune responses while minimizing systemic safety issues. Its major product candidates include JANX007 for prostate cancer, JANX008 for solid tumors, and JANX009 for HER2-positive cancers. The company generates revenue through collaborations, licensing agreements, and milestone payments from strategic partnerships.

Janux Therapeutics, Inc. is headquartered in San Diego, California, United States. The company has plans for global expansion through new markets and partnerships, but currently has no established geographic footprint beyond its U.S. operations.

The most notable event affecting Janux Therapeutics' brand reputation in the past year was the updated interim Phase 1 clinical data for JANX007 in December 2025, which led to a stock price drop and analyst downgrades. Janux Therapeutics earned a "Great Place To Work Certification™" in 2024, reflecting a positive internal reputation.

Janux Therapeutics, Inc. has significant institutional ownership, with 181 institutional owners holding a total of 61,667,018 shares. Major institutional shareholders include Ra Capital Management, Janus Henderson Group Plc, BlackRock, Inc., State Street Corp, Fmr Llc, Vanguard Group Inc, Prosight Management, LP, Orbimed Advisors Llc, TCG Crossover Management, LLC, and Wellington Management Group Llp. Avalon Ventures XI LP is the largest individual shareholder, owning 19.49% of the company's shares. Insider selling by the President, David Campbell, was observed in January 2026.